Company Information

MEDPLUS HEALTH SERVICES LTD.

NSE : MEDPLUSBSE : 543427ISIN CODE : INE804L01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE681.30-0.6 (-0.09 %)
PREV CLOSE ( ) 681.90
OPEN PRICE ( ) 673.25
BID PRICE (QTY) 681.05 (2)
OFFER PRICE (QTY) 682.65 (3)
VOLUME 1214
TODAY'S LOW / HIGH ( )673.25 690.00
52 WK LOW / HIGH ( )597.95 977.45
NSE683.10-0.2 (-0.03 %)
PREV CLOSE( ) 683.30
OPEN PRICE ( ) 683.30
BID PRICE (QTY) 682.30 (1)
OFFER PRICE (QTY) 683.10 (31)
VOLUME 41771
TODAY'S LOW / HIGH( ) 678.10 691.95
52 WK LOW / HIGH ( )598.6 978
ChairmanGangadi Madhukar Reddy
Managing DirectorGangadi Madhukar Reddy
Company SecretaryManoj Kumar Srivastava
Non Executive DirectorAnish Kumar Saraf
Non Executive Independent DirectorHiroo Mirchandani
Madhavan Ganesan
Murali Sivaraman
Whole Time DirectorCherukupalli Bhaskar Reddy
Incorporation Year : 30-11 2006

Registered Office :

Address : H. No: 11-6-56, Survey No: 257 & 258/1,Opp: I D P L Railway Siding Road,Moosapet, Kukatpally Hyderabad,
Telangana-500037 .

Phone : 040-67246724

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.